CLINICAL TRIALS PROFILE FOR QUESTRAN
✉ Email this page to a colleague
All Clinical Trials for QUESTRAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01053065 ↗ | The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study | Completed | Biomedical Foundation for Cardiovascular Research of Padova | N/A | 1969-12-31 | The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells. |
| NCT01053065 ↗ | The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study | Completed | Pfizer | N/A | 1969-12-31 | The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells. |
| NCT01053065 ↗ | The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study | Completed | University of Padova | N/A | 1969-12-31 | The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells. |
| NCT01053065 ↗ | The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study | Completed | University of Padua | N/A | 1969-12-31 | The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells. |
| NCT01062269 ↗ | A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study | Completed | Daiichi Sankyo Inc. | Phase 4 | 2010-01-01 | The purpose of the research study is (1) to rate the taste, texture, appearance, and mixability of 2 different doses of orange flavored cholestyramine compared to orange flavored Tang, (2) rank the importance of the taste, texture, appearance, and mixability when rating cholestyramine and Tang to determine the accuracy and usefulness of a taste test questionnaire. |
| NCT01062269 ↗ | A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study | Completed | Daiichi Sankyo, Inc. | Phase 4 | 2010-01-01 | The purpose of the research study is (1) to rate the taste, texture, appearance, and mixability of 2 different doses of orange flavored cholestyramine compared to orange flavored Tang, (2) rank the importance of the taste, texture, appearance, and mixability when rating cholestyramine and Tang to determine the accuracy and usefulness of a taste test questionnaire. |
| NCT01062269 ↗ | A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study | Completed | Provident Clinical Research | Phase 4 | 2010-01-01 | The purpose of the research study is (1) to rate the taste, texture, appearance, and mixability of 2 different doses of orange flavored cholestyramine compared to orange flavored Tang, (2) rank the importance of the taste, texture, appearance, and mixability when rating cholestyramine and Tang to determine the accuracy and usefulness of a taste test questionnaire. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for QUESTRAN
Condition Name
Clinical Trial Locations for QUESTRAN
Trials by Country
Clinical Trial Progress for QUESTRAN
Clinical Trial Phase
Clinical Trial Sponsors for QUESTRAN
Sponsor Name
